Suppr超能文献

用于癌症治疗的天然产物与小RNA的联合递送:综述

The Co-Delivery of Natural Products and Small RNAs for Cancer Therapy: A Review.

作者信息

Wang Xuyi, Li Shuang, Wang Zelong, Kang Baorong, Yan Hong

机构信息

School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.

出版信息

Molecules. 2025 Mar 27;30(7):1495. doi: 10.3390/molecules30071495.

Abstract

This review summarizes the research progress in the co-delivery of natural products (NPs) and small RNAs in cancer therapy. NPs such as paclitaxel, camptothecin, and curcumin possess multi-target antitumor effects, but their applications are limited by drug resistance and non-specific distribution. Small RNAs can achieve precise antitumor effects through gene regulation, yet their delivery efficiency is low, and they are prone to degradation by nucleases. Nanomaterial-based drug delivery systems (nano-DDSs) provide an efficient platform for the co-delivery of both, which can enhance the targeting of their delivery and improve the synergistic antitumor effects simultaneously. The mechanisms of the antitumor action of natural compounds and small RNAs, the design and application of nanocarriers, and the latest research progress in co-delivery systems are introduced in detail in this paper. The application prospects of the co-delivery of natural compounds and small RNAs in cancer therapy are also discussed.

摘要

本综述总结了天然产物(NPs)与小分子RNA联合递送在癌症治疗中的研究进展。紫杉醇、喜树碱和姜黄素等天然产物具有多靶点抗肿瘤作用,但其应用受到耐药性和非特异性分布的限制。小分子RNA可通过基因调控实现精确的抗肿瘤作用,但其递送效率较低,且易被核酸酶降解。基于纳米材料的药物递送系统(纳米DDSs)为二者的联合递送提供了一个高效平台,可增强其递送的靶向性,同时提高协同抗肿瘤效果。本文详细介绍了天然化合物和小分子RNA的抗肿瘤作用机制、纳米载体的设计与应用以及联合递送系统的最新研究进展。还讨论了天然化合物与小分子RNA联合递送在癌症治疗中的应用前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa8/11990496/afeaeae8ddbc/molecules-30-01495-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验